Halozyme Therapeutics, Inc.
HALO
$74.93
$1.532.08%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 34.97% | 25.65% | 22.44% | 21.35% | 12.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.97% | 25.65% | 22.44% | 21.35% | 12.88% |
| Cost of Revenue | 5.21% | -10.37% | -24.96% | -18.08% | -13.75% |
| Gross Profit | 44.81% | 40.11% | 45.16% | 41.01% | 25.72% |
| SG&A Expenses | 16.52% | 9.94% | 3.45% | 17.48% | 13.51% |
| Depreciation & Amortization | -0.11% | -0.21% | -0.31% | 22.37% | 5.51% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.82% | 1.18% | -5.18% | 5.63% | 5.17% |
| Operating Income | 68.73% | 56.48% | 62.16% | 42.20% | 23.37% |
| Income Before Tax | 66.09% | 54.27% | 59.94% | 51.00% | 43.75% |
| Income Tax Expenses | 69.81% | 63.08% | 69.39% | 36.84% | 41.34% |
| Earnings from Continuing Operations | 65.22% | 52.25% | 57.71% | 54.57% | 44.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.22% | 52.25% | 57.71% | 54.57% | 44.32% |
| EBIT | 68.73% | 56.48% | 62.16% | 42.20% | 23.37% |
| EBITDA | 57.78% | 46.86% | 50.41% | 38.69% | 20.03% |
| EPS Basic | 71.10% | 57.10% | 63.48% | 61.49% | 50.70% |
| Normalized Basic EPS | 77.48% | 64.59% | 71.40% | 52.23% | 34.42% |
| EPS Diluted | 69.17% | 55.18% | 62.32% | 60.60% | 50.85% |
| Normalized Diluted EPS | 76.05% | 63.33% | 70.67% | 52.12% | 34.94% |
| Average Basic Shares Outstanding | -3.35% | -3.10% | -3.88% | -4.50% | -4.36% |
| Average Diluted Shares Outstanding | -2.54% | -2.38% | -3.60% | -4.57% | -4.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |